Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 14, 2004 - Issue 4
Submit an article Journal homepage
30
Views
1
CrossRef citations to date
0
Altmetric
Review

Recent advances in the treatment of psoriatic arthritis

Nicolò Pipitone Rheumatology Unit, GKT School of Medicine, Guy's Campus, London, SE1 9RT, UK. [email protected]
&
Costantino Pitzalis Rheumatology Unit, GKT School of Medicine, Guy's Campus, London, SE1 9RT, UK. [email protected]
Pages 509-525 | Published online: 22 Apr 2005

Bibliography

  • BLUMBERG BS, BUNIM JJ, CALKINS E, PIRANI CL, ZVAIFLER NJ: ARA nomenclature and classification of arthritis and rheumatism (tentative). Arthritic Rheumatism (1964) 7:93–97.
  • WRIGHT V: A unifying concept for the spondyloarthropathies. Clin. Orthop. (1979):8–14.
  • MCGONAGLE D, KHAN MA, MARZO-ORTEGA H, O'CONNOR P, GIBBON W, EMERY P: Enthesitis in spondyloarthropathy. Can: Opin. Rheumatol. (1999) 11:244–250.
  • MCGONAGLE D, GIBBON W, O'CONNOR P, GREEN M, PEASE C, EMERY P: Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritic Rheum. (1998) 41:694–700.
  • MCGONAGLE D, GIBBON W, EMERY P: Classification of inflammatory arthritis by enthesitis. Lancet (1998) 352:1137–1140.
  • GLADMAN DD, FAREWELL VT, WONG K, HUSTED J: Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritic. Rheum. (1998) 41:1103–1110.
  • ESPINOZA LR, CUELLAR ML: Psoriatic arthritis: management. In: Rheumatology. JH Klippel, PA Dieppe (Eds) Mosby, London, UK (1998):1–6.
  • HUIZINGA TW, KEIJSERS V, YANNI G et al: Are differences in interleukin-10 production associated with joint damage? Rheumatology (2000) 39:1180–1188.
  • HOHLER T, MARKER-HERMANN E: Psoriatic arthritis: clinical aspects, genetics, and the role of T cells. Carr: Opin. Rheumatol. (2001) 13:273–279.
  • BREATHNACH SM: Psoriatic arthritis: etiology and pathogenesis. In: Rheumatology Klippel JH, Dieppe P (Eds) Mosby, Philadelphia, USA (1998):1–4.
  • GRIFFITHS CE, VOORHEES JJ: Psoriasis, T cells and autoimmunity. R. Soc. Med. (1969) 89:315–319.
  • COSTELLO PJ, WINCHESTER RJ, CURRAN SA et al.: Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. Immunol . (2001) 166:2878–2886.
  • SCARPA R, MANGUSO F, D 'ARIENZO A et al: Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. Rheumatol . (2000) 27:1241–1246.
  • PORZIO V, BIASI G, CORRADO A et al:Intestinal histological and ultrastructural inflammatory changes in spondyloarthropathy and rheumatoid arthritis. Scand.j. Rheumatol (2000) 26:92–98.
  • TROUGHTON PR, MORGAN AW: Laboratory findings and pathology of psoriatic arthritis. Baillieres Clin. Rheumatol. (1994) 8:439–463.
  • LUQMANI R, SHEERAN T, ROBINSON M, RICHARDSON K, WINKLES J, EMERY P: Systemic cytokine measurements: their role in monitoring the response to therapy in patients with rheumatoid arthritis. (1994) Clin. Exp. Rheumatol. 12: 503–508.
  • BARKER JN: The immunopathology ofpsoriasis. Baillieres Clin. Rheumatol. (1994) 8:429–438.
  • PITZALIS C, KINGSLEY G, HASKARD D, PANAYI G: The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion. Ear: Immunol. (1998) 18:1397–1404.
  • PITZALIS C, KINGSLEY G, LAN CHBURY JS, MURPHY J, PANAYI GS: Expression of HLA-DR, DQ and DP antigens and interleukin-2 receptor on synovial fluid T lymphocyte subsets in rheumatoid arthritis: evidence for 'frustrated' activation. Rheumatol. (1987) 14:662–666.
  • COSTELLO P, BRESNIHAN B, O'FARRELLY C, FITZGERALD 0: Predominance of CD8+ T lymphocytes in psoriatic arthritis. Rheumatol. (1999) 26:1117–1124.
  • SCARPA R, MATHIEU A: Psoriatic arthritis: evolving concepts. Curt: Opin. Rheumatol. (2000) 12:274–280.
  • TASSIULAS I, DUNCAN SR, CENTOLA M, THEOFILOPOULOS AN, BOUMPAS DT: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum. Immunol. (1999) 60:479–491.
  • PITZALIS C: Skin and joint disease in psoriatic arthritis: what is the link? Br. Rheumatol. (1998) 37:480–483.
  • WRONE-SMITH T, NICKOLOFF BJ: Dermal injection of immunocytes induces psoriasis' Clin. Invest. (1996) 98:1878–1887.
  • SCHON MP, DETMAR M, PARKER CM: Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat. Medicine (1997) 3:183–188.
  • PITZALIS C, CAULI A, PIPITONE N et al.: Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritic Rheum. (1996) 39:137–145.
  • JONES SM, ARMAS JB, COHEN MG, LOVELL CR, EVISON G, MCHUGH NJ: Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br. Rheumatol. (1994) 33:834–839.
  • DANNING CL, ILLEI GG, HITCHON C, GREER MR, BOUMPAS DT, MCINNES IB: Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritic Rheum. (2000) 43:1244–1256.
  • KONIG A, KRENN V, GILLITZER R et al: Inflammatory infiltrate and interleukin-8 expression in the synovium of psoriatic arthritis-an immunohistochemical and mRNA analysis. Rheumatol. Int. (1997) 17:159–168.
  • KONIG A, KRENN V, GILLITZER R et al.: Inflammatory infiltrate and interleukin-8 expression in the synovium of psoriatic arthritis-an immunohistochemical and mRNA analysis. Rheumatol. Int. (1997) 17:159–168.
  • VEALE D, YANNI G, ROGERS S, BARNES L, BRESNIHAN B, FITZGERALD 0: Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritic Rheum. (1993) 36:893–900.
  • REECE RJ, CANETE JD, PARSONS WJ, EMERY P, VEALE DJ: Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritic Rheum. (1999) 42:1481–1484.
  • CANETE JD, MARTINEZ SE, FARRES J et al.: Differential TH1/TH2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann. Rheum. Dis. (2000) 59:263–268.
  • PARTSCH G, WAGNER E, LEEB BE BROLL H, DUNKY A, SMOLEN JS: T cell-derived cytokines in psoriatic arthritis synovial fluids. Ann. Rheum. Dis. (1998) 57:691–693.
  • NISHIBU A, HAN GW, IWATSUKI K et al.: Overexpression of monocyte-derived cytokines in active psoriasis: a relation to coexistent arthropathy.f Dermatol Sci. (1999) 21:63–70.
  • JACKSON JR, BOLOGNESE B, HILLEGASS L et al.: Pharmacological effects of SB-220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.' Pharmacol Exp. Ther. (1998) 284:687–692.
  • MEASE PJ: Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann. Rheum. Dis. (2002) 61:298–304.
  • BRAUN J, DE KEYSER F, BRANDT J, MIELANTS H, SIEPER J, VEYS E: New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Carr: Opin. Rheumatol (2001) 13:245–249.
  • MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385–390.
  • PARTSCH G, STEINER G, LEEB DUNKY A, BROLL H, SMOLEN JS: Highly increased levels of tumor necrosis factor-a and other proinflammatory cytokines in psoriatic arthritis synovial fluid. Rheumatol (1997) 24:518–523.
  • ELKAYAM 0, YARON I, SHIRAZI I, YARON M, CASPI D: Serum levels of IL-10, IL-6, IL- lra, and sIL-2R in patients with psoriatic arthritis. Rheumatol hat. (2000) 19:101–105.
  • PUNZI L, BERTAZZOLO N, PIANON M, RIZZI E, ROSSINI P, GAMBARI P: Value of synovial fluid interleukin-1 13 determination in predicting the outcome of psoriatic monoarthritis. Ann. Rheum. Dis. (1996) 55:642–644.
  • WATT I, COBBY M: Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment. Semin. Arthritis Rheum. (2001) 30:21–25.
  • ST CLAIR EW: Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann. Rheum. Dis. (2002) 61\(Supp1.2):ii67-ii69.
  • ZIFF M: Role of cytokines in rheumatoid synovitis. Scand.J. Rheumatol (1998) 76(Suppl.):211–215.
  • BRENNAN FM, MAINI RN, FELDMANN M Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin. brimunopathoL (1998) 20:133–147.
  • SCHRIEBER KD, JACKSON CL: Angiogenesis in rheumatoid arthritis. In: Rheumatology Klippel JH, Dieppe PA (Eds) Mosby, Philadelphia, USA 12.1-12.4.
  • BRENCHLEY PE: Antagonising angiogenesis in rheumatoid arthritis. Ann. Rheum. Dis. (2003) 60\(Supp1.3):iii71-iii74.
  • MURPHY G, HEMBRY RM: Proteinases in rheumatoid arthritis. (1992) Rheumatol 32 (Suppl.) :61–64.
  • RICKARD DJ, GOWEN M: Cytokines in arthritis. In: Collected reports on the rheumatic diseases. Butler RC, Jayson MIV (Eds) Arthritis Research Campaign, Chesterfield, UK (2003):251–255.
  • MONCADA S: The 1991 Ulf von Euler Lecture. The L-arginine-nitric oxide pathway. Acta. Physiol Scand. (1992) 145:201–227.
  • STEFANOVIC-RACIC M, STADLER J,EVANS CH: Nitric oxide and arthritis. Arthritis Rheum. (1993) 36:1036–1044.
  • ABRAMSON SB, AMIN AR, CLANCY RM, ATTUR M: The role of nitric oxide in tissue destruction. (2001) Best Piaci Res. Clin. Rheumatol 15:831–845.
  • LOTZ M: Neuropeptides and free radicalsin rheumatoid arthritis. In: Rheumatology. Klippel JH, Dieppe PA (Eds) Mosby, Philadelphia, USA (2003):11.1-11.10.
  • ST CLAIR EW, WILKINSON WE, LANG T et al.: Increased expression of blood mononuclear cell nitric oxide synthase Type 2 in rheumatoid arthritis patients. (1996) Exp. Med. 184: 1173–1178.
  • DROSOS AA: Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy. (2002) Drugs 62:891–907.
  • SAXENA M, MUSTELIN T: Extracellular signals and scores of phosphatases: all roads lead to MAP kinase. (2000) Semin. Immunol 12:387–396.
  • LEE JC, KUMAR S, GRISWOLD DE, UNDERWOOD DC,VOTTA BJ, ADAMS JL: Inhibition of p38 MAP kinase as a therapeutic strategy. (2000) brimunopharmacology47:185–201.
  • LEE JC, YOUNG PR: Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. (1996) Leukoc. Biol. 59: 152–157.
  • DONG C, DAVIS RJ, FLAVELL RA: Signaling by the JNK group of MAP kinases. c-jun N-terminal kinase. Clin. brimunol. 21:253–257 (2001).
  • SCHETT G, TOHIDAST-AKRAD M, SMOLEN JS et al.: Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 43:2501–2512 (2000).
  • CRAWLEY JB, RAWLINSON L, LALI FV, PAGE TH, SAKLATVALA J, FOXWELL BM: T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. (1997) J. Biol. Chem. 272: 15023–15027.
  • LEONARD WJ, LIN JX: Cytokine receptor signaling pathways. (2000) Allergy Clin. Immunol 105:877–888.
  • HORVATH CM, DARNELL JE: The state of the STATs: recent developments in the study of signal transduction to the nucleus. Carr: Opin. Cell Biol. (1997) 9:233–239.
  • IMADA K, LEONARD WJ: The Jak-STATpathway. (2000) MM. Immunol 37:1–11.
  • MASUDA A, MATSUGUCHI T, YAMAKI K et al.: Interleukin-15 induces rapid tyrosine phosphorylation of STAT6 and the expression of interleukin-4 in mouse mast cells. J. Biol. Chem. (2000) 275:29331–29337.
  • BENNEDSEN M, WANG X, WILLEN R, WADSTROM T, ANDERSEN LP: Treatment of H pylori infected mice with antioxidant astaxanthin reduces gastric inflammation, bacterial load and modulates cytokine release by splenocytes. brimunol . Lett. (1999) 70:185–189.
  • OHGAMI K, SHIRATORI K, KOTAKE Set al.: Effects of astaxanthin on lipopolysaccharide-induced inflammation M vitro and M vivo. Invest. Ophthalmol Vis. Sci. (2003) 44:2694–2701.
  • KURASHIGE M, OKIMASU E, INOUE M, UTSUMI K: Inhibition of oxidative injury of biological membranes by astaxanthin. Physiol Chem. Phys. Med. (1990) NMR22:27–38.
  • SCHREIBER SL: Chemistry and biology ofthe immunophilins and their immunosuppressive ligands. Science (1991) 251:283–287.
  • SIGAL NH, DUMONT FJ: Cyclosporin A, FK506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann. Rev Immunol (1992) 10:519–560.
  • JAIN J, MCCAFFREY PG, MINER Z et al: The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature (1993) 365:352–355.
  • JEGASOTHY BV, ACKERMAN CD, TODO S, FUNG JJ, ABU-ELMAGD K, STARZL TE: Tacrolimus (FK506)-a new therapeutic agent for severe recalcitrant psoriasis. Arch. Dermatol (1992) 128:781–785.
  • SALVARANI C, MACCHIONI P, OLIVIERI I et al.: A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J. Rheumatol (2001) 28:2274–2282.
  • NAKAZATO H, OKU H, YAMANE S, TSURUTA Y, SUZUKI R: A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-a at the translational level. Eur. Pharmacol (2002) 446:177–185.
  • BYGBJERG IC, SVENSON M, THEANDER TG, BENDTZEN K: Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytes. Int . I Immunopharmacol (1987) 9:513–519.
  • PEDERSEN BK, BYGBJERG IC, THEANDER TG, ANDERSEN BJ: Effects of chloroquine, mefloquine and quinine on natural killer cell activity in vitro. An analysis of the inhibitory mechanism. Allergy (1986) 41:537–542.
  • DUAN H, KOGA T, KOHDA F, HARA H, URABE K, FURUE M: Interleukin-8-positive neutrophils in psoriasis. Dermatol Sci. (2001) 26:119–124.
  • GIUSTIZIERI ML, MASCIA F, FREZZOLINI A et al: Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. I Allergy Clin. Immunol (2001) 107:871–877.
  • SCHULZ BS, MICHEL G, WAGNER S et al.: Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. I Immunol (1993) 151:4399–4406.
  • GILLITZER R, RITTER U, SPANDAU U, GOEBELER M, BROCKER EB: Differential expression of GRO-a and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in viva J. Invest. Dermatol (1996) 107:778–782.
  • BRUCH-GERHARZ D, FEHSEL K, SUSCHEK C, MICHEL G, RUZICKA T, KOLB-BACHOFEN V: A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes. Exp. Med. (1996) 184:2007–2012.
  • KRAAN MC, VAN KUIJK AW, DINANT HJ et al.: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritic Rheum. (2002) 46:2776–2784.
  • JOHNSTON B, CHEE A, ISSEKUTZ TB et al.: a4 Integrin-dependent leukocyte recruitment does not require VCAM-1 in a chronic model of inflammation. Immunol (2000) 164:3337–3344.
  • PALEOLOG EM: Angiogenesis in rheumatoid arthritis. Arthritic. Res. (2002) 4: (Supp1.3):S81–S90.
  • JOHNSTON SR: Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. (2001) Lancet Oncol 2:18–26.
  • PREVOST GP, PRADINES A, BREZAK MC et al: Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228. Int. Cancer (2001) 91:718–722.
  • PARK JY, KWON BM, CHUNG SK, KIM JH, J00 CK: Inhibitory effect of 2'- 0-benzoylcinnamaldehyde on vascular endothelial cell proliferation and migration. Ophthalmic Res. (2001) 33:111–116.
  • END DW, SMETS G, TODD AV et al: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R-115777 M vivo and in vitro. Cancer Res. (2001) 61:131–137.
  • FITZPATRICK LR, BOST WICK JS, RENZETTI M, PENDLETON RG, DECKTOR DL: Anti-inflammatory effects of various drugs on acetic acid induced colitis in the rat. Agents Actions (1990) 30:393–402.
  • OHUCHI K, WATANABE M, HIRASAWA N, TSURUFUJI S, OZEKI T, FUJIKI H: Inhibition by gossypol of tumor promoter-induced arachidonic acid metabolism in rat peritoneal macrophages. Biochim. Biophys. Acta. 971:85–91 (1988).
  • MARTEL-PELLETIER J, WELSCH DJ,PELLETIER JP: Metalloproteases and inhibitors in arthritic diseases. Best Pract. Res. Clin. Rheumatol 15:805–829 (2001).
  • KUETTNER KE, THONAR EJMA: Cartilage integrity and homeostasis. In: Rheumatology. Klippel JH, Dieppe PA (Eds) Mosby, Philadelphia, USA (1998):6.1-6.13.
  • TIERNEY GM, GRIFFIN NR, STUART RC et al.: A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur. J. Cancer (1999) 35:563H568.
  • DENIS LJ, VERWEIJ J: Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest. New Drugs (1997) 15:175–185.
  • KELLY BA, BOND BC, POSTON L: Gestational profile of matrix metalloproteinases in rat uterine artery. MM. Hum. Reprod. (2003) 9:351–358.
  • FORTUNATO SJ, MENON R: Screening of novel matrix metalloproteinases (MMPs) in human fetal membranes. I Assist. Reprod. Genet. (2002) 19:483–486.
  • MORRIS CJ, EARL JR, TRENAM CW, BLAKE DR: Reactive oxygen species and iron-a dangerous partnership in inflammation. Int.' Biochem Cell. Biol. (1995) 27:109–122.
  • WINROW VR, WINYARD PG, MORRIS CJ, BLAKE DR: Free radicals in inflammation: second messengers and mediators of tissue destruction. Br. Med. Bull. (1993) 49:506–522.
  • BLAKE DR, MERRY P, STEVENS C et al.: Iron free radicals and arthritis. Proc. Num Soc. (1990) 49:239–245.
  • BIASI D, CARLETTO A, CARAMASCHI P et al.: Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis. Inflammation (1998) 22:533–543.
  • ENGLISH JM, COBB MH: Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. (2002) 23:40–45.
  • BADGER AM, COOK MN, LARK MW et al.: SB-203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. Immunol (1998) 161:467–473.
  • BORSCH-HAUBOLD AG, PASQUET S, WATSON SP: Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB-203580 and PD-98059. SB-203580 also inhibits thromboxane synthase. Biol Chem. (1998) 273:28766–28772.
  • BADGER AM, GRISWOLD DE, KAPADIA R et al.: Disease-modifying activity of SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. (2000) 43:175–183.
  • ARBABI S, MAIER RV: Mitogen-activated protein kinases. Crit. Care Med. (2002) 30:S74–S79.
  • GALLAGHER TF, SEIBEL GL, KASSIS S et al.: Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. (1997) 5:49–64.
  • PETROVSKY N, HARRISON LC: The chronobiology of human cytokine production. Int. Rev Immunol (1998) 16:635–649.
  • IMBERT AM, PIGNON T, LENA N: Enzymatic assay for methotrexate with a centrifugal analyzer (Cobas-Bio). Clin. Chem. (1983) 29:1317–1318.
  • LACAILLE D, STEIN HB, RABOUD J, KLINKHOFF AV: Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate?.1. Rheumatol (2000) 27:1922–1927.
  • JONES G, CROTTY M, BROOKS P: Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. Br. Rheumatol. (1997) 36:95–99.
  • SALAFFI F, MANGANELLI P, CAROTTI M, SUBIACO S, LAMANNA G, CERVINI C: Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin. Rheumatol (1997) 16:296–304.
  • SARZI-PUTTINI P, SANTANDREA S, BOCCASSINI L, PANNI B, CARUSO I: The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin. Exp. Rheumatol. (2001) 19:S17–S20.
  • RAINSFORD KD: Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rheumatology (Oxford) (1999) 38\(Supp1.1):4–10.
  • TAVARES IA, BORRELLI F, WELSH NJ: Inhibition of gastric acid secretion by nimesulide: a possible factor in its gastric tolerability. Clin. Exp. Rheumatol (2001) 19:S13–S15.
  • SHAH AA, THJODLEIFSSON B, MURRAY FE et al.: Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut (2001) 48:339–346.
  • KAPICIOGLU S, BAKI AH, SARI M, OZDEMIR F, KAVGACI H: Does nimesulide induce gastric mucosal damage? 'A double-blind randomized placebo-controlled trial'. Hepatogastroenterology (2000) 47:1183–1185.
  • PORTO A, ALMEIDA H, CUNHA MJ, MACCIOCCHI A: Double-blind study evaluating by endoscopy the tolerability of nimesulide and diclofenac on the gastric mucosa in osteoarthritic patients. Eui: Rheumatol Inflamm. (1994) 14:33–38.
  • GRIFFITHS CE: Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. Br. Rheumatol (1997) 36:409–410.
  • ELLIS CN, FALLON JD, KANG S, VANDERVEEN EE, VOORHEES JJ: Topical application of non-steroidal anti-inflammatory drugs prevents vehicle-induced improvement of psoriasis. Am. Acad. Dermatol. (1986) 14:39–43.
  • ELLIS CN, GOLDFARB MT, ROENIGK HH Jr, ROSENBAUM M, WHEELERS, VOORHEES JJ: Effects of oral meclofenamate therapy in psoriasis. Am . Acad. Dermatol (1986) 14:49–52.
  • CHUANG SE, CHENG AL, LIN JK, KUO ML: Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell cycle-related proteins in rats. Food Chem. Toxicol (2000) 38:991–995.
  • LIM GP, CHU T, YANG F, BEECH W, FRAUTSCHY SA, COLE GM: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Neurosci. (2001) 21:8370–8377.
  • OKADA K, WANGPOENGTRAKUL C, TANAKA T, TOYOKUNI S, UCHIDA K, OSAWA T: Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injury in mice. I Num. (2001) 131:2090–2095.
  • LI JK, LIN-SHIA SY: Mechanisms of cancer chemoprevention by curcumin. Proc. Nati Sci. Count.. Repub. China B (2001) 25:59–66.
  • CHENG AL, HSU CH, LIN JK et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. (2001) 21:2895–2900.
  • HENG MC, SONG MK, HARKER J, HENG MK: Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br. Dermatol (2000) 143:937–949.
  • SNELLMAN E, LAUHARANTA J, REUNANEN A et al.: Effect of heliotherapy on skin and joint symptoms in psoriasis: a 6-month follow-up study. Br. .1 Dermatol (1993) 128:172–177.
  • VAHLQUIST C, LARSSON M, ERNERUDH J, BERLIN G, SKOGH T, VAHLQUIST A: Treatment of psoriatic arthritis with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation. Arthritis Rheum. (1996) 39:1519–1523.
  • BRAND A, GRIFFITHS DJ, HERVE C, MALLON E, VENABLES PJ: Human retrovirus-5 in rheumatic disease. Autoimmun. (1999) 13:149–154.
  • NAGPAL S, CHANDRARATNA RA: Vitamin A and regulation of gene expression. Carr: Opin. Clin. Num Metab. Care (1998) 1:341–346.
  • ZOUBOULIS CC: Retinoids-which dermatological indications will benefit in the near future? SIMI PharmacoL AppL Sat Physiol (2001) 14:303–315.
  • DIAZ BV, LENOIR MC, LAD OUX A, FRELIN C, DEMARCHEZ M, MICHEL S: Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. BioL Chem. (2000) 275:642–650.
  • SJOGREN F, STENDAHL 0, LJUNGHUSEN 0: The influence of retinoic acid and retinoic acid derivatives on 12 integrins and L-selectin expression in HL-60 cells M vitro. Inflammation (2000) 24:21–32.
  • KRUEGER GG, DRAKE LA, ELIAS PM et al: The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch. Dermatol (1998) 134:57–60.
  • HOPKINS R, BIRD HA, JONES H et al: A double-blind controlled trial of etretinate (tigason) and ibuprofen in psoriatic arthritis. Ann. Rheum. Dis. (1985) 44:189–193.

Websites

  • www.nice.org.uk National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance no. 27 - guidance on the use of cyclo-oxygenase (Cox) II-selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis (2001):1–15.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.